SGK1 and Prolonged QT interval: ▪Therapeutically inhibiting SGK1 with our novel SGK1 inhibitor effectively shortens the action potential duration (the cellular surrogate for the QT interval) in human iPSC-CM models of all 3 major long QT syndrome genotypes.